YZYuwei Zhu

Yuwei Zhu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Yuwei Zhu has a total of 456 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Influenza Vaccine Effectiveness Against Influenza A–Associated Hospitalization and Severe In-Hospital Outcomes Among Adults in the United States, 2024–2025

    byĀ Nathaniel M Lewis, Seana Cleary, Elizabeth J Harker, Basmah Safdar, Adit A Ginde, Ithan D Peltan, Manjusha Gaglani, Cristie Columbus, Emily T Martin, Adam S Lauring, et al.

    Background: The US 2024–2025 influenza season was characterized by sustained elevated activity from November 2024 to April 2025, with circulation of both influenza A(H1N1)pdm09 and A(H3N2), the latter of which included some antigenically drifted viruses. Methods: From 1 October 2024 to 30 April 2025, a multistate respiratory virus surveillance network enrolled adults hospitalized with acute respiratory illness in 26 US medical centers. Influenza vaccine effectiveness (VE) against influenza-associated hospitalization and severe in-hospital outcomes was estimated using a test-negative study. The odds of influenza vaccination among influenza-positive case patients and influenza-negative control patients were compared using multivariable logistic regression; VE was calculated as (1āˆ’adjusted odds ratio for vaccination) Ɨ 100, expressed as a percent. Results: The 2024–2025 seasonal influenza vaccine was effective against influenza-associated hospitalization (VE: 40% [95% confidence interval (CI): 32%–47%]), consistent across age group and influenza type/A subtype. Influenza vaccination also reduced the overall risk of all severe in-hospital outcomes evaluated, including standard oxygen therapy (VE: 41% [95% CI: 31%–50%]), noninvasive advanced respiratory support (VE: 38% [95% CI: 19%–52%]), invasive organ support (VE: 58% [95% CI: 44%–69%]), intensive care unit admission (VE: 58% [95% CI: 47%–67%]), and death (VE: 52% [95% CI: 18%–71%]) with effectiveness varying by influenza A subtype and age. Conclusions: Influenza vaccination reduced the risk of influenza-related hospitalization and severe in-hospital outcomes in adults during the severe 2024–2025 influenza season compared with those not vaccinated.

  • Characterizing Oseltamivir Use Among Community-Dwelling Patients Diagnosed With Influenza Virus Infection, 2023–2025

    byĀ Emily A McNair, Jennie H Kwon, Carlos G Grijalva, Son H McLaren, Jessica E Biddle, Samantha Dean, Lydia Bristol, Elizabeth B White, Stephanie A Fritz, Rachel M Presti, et al.

    Background: Oseltamivir is an antiviral medication for influenza that can reduce the duration of symptoms and may lower the risk of some complications. Recommendations for use of oseltamivir include in the outpatient setting for individuals at higher risk of developing influenza complications. The objectives of the current study were to describe oseltamivir initiation and treatment completion among influenza-positive outpatients and identify factors associated with each. Methods: In a US outpatient household transmission study, index participants with laboratory-confirmed influenza provided up to 12 days of detailed information on medication use. We described oseltamivir initiation among index case patients and treatment course completion of ≄10 doses among patients who started oseltamivir. We used adjusted logistic regression to identify factors associated with initiation and course completion. Results: Among 823 enrolled index patients, 324 (39%) initiated oseltamivir treatment. Of 406 persons at higher risk for influenza complications, 172 (42%) initiated treatment. Oseltamivir initiation was lowest among children aged 2–4 years (19%), compared with all other age groups. After exclusion of the likely censored cases, 133 of 313 patients (42%) completed the recommended treatment course. Among 163 individuals at higher risk of influenza complications, 69 (42%) completed the recommended treatment course. Children <2 years old were significantly less likely to complete treatment than adults aged 18–50 years (adjusted odds ratio, 0.21 [95% confidence interval, .04–.78; P = .03); the reasons for discontinuation could not be determined. Conclusions: In this population in the outpatient setting, fewer than half of persons at higher risk for influenza complications initiated oseltamivir treatment, and fewer than half of those who initiated treated completed it.

  • Influenza mitigation recommendations, symptoms, and viral RNA shedding durations—2023-2024 and 2024-2025 seasons

    byĀ Elizabeth B White, Caroline A O’NEil, Melissa S Stockwell, Son H McLaren, Ellen Sano, Celibell Y Vargas, Henry C Fremont, Stacey House, Rachel M Presti, Stephanie A Fritz, et al.

    In March 2024, the Centers for Disease Control and Prevention (CDC) released symptom-based isolation guidance for viral respiratory illnesses including influenza: isolation from others until fever-free for 24 h and other symptoms are improving, followed by 5 days of post-isolation precautions. This study evaluated how well these recommendations aligned with influenza virus RNA shedding and assessed self-reported isolation in a multi-site household study during 2023-2025. We analyzed data from 1294 participants with influenza, including 627 with a clear peak in viral RNA levels and symptom resolution during follow-up. Participants provided daily symptom diaries and nasal swabs. We used Kaplan–Meier models to estimate recommended isolation duration based on CDC guidelines and compared this to viral RNA shedding measured by cycle threshold (Ct) values and viral loads (VLs). The median recommended isolation duration was 6 days (IQR 4-7). Peak viral RNA shedding occurred a median of 4 days post-symptom onset, falling during recommended isolation for 80% (by Ct) and 69% (by VL) of participants and increasing to 100% and 97%, respectively, by day 6 post-isolation. However, only 21% reported isolating from household members (median 2 days), and 80% isolated from the community (median 4 days). These findings support symptom-based isolation and emphasize the importance of post-isolation precautions.

  • Open Access

    Influenza Vaccination and Symptom Burden in Ambulatory Patients With Confirmed Influenza: Evidence From Case-ascertained Household Transmission Studies

    byĀ Amanda C Howa, Yuwei Zhu, Trey McGonigle, Huong Q Nguyen, Melissa S Stockwell, Yvonne Maldonado, Karen Lutrick, Natalie M Bowman, Suchitra Rao, Jonathan Schmitz, et al.

    Background: The extent to which influenza vaccination may temper disease remains uncertain. We compared symptoms between influenza vaccinated and unvaccinated ambulatory persons with influenza. Methods: We conducted household transmission studies across multiple US sites during consecutive influenza seasons from 2017–2018 through 2022–2023 (excluding 2020–2021 season with minimal influenza activity). We collected daily symptom diaries and respiratory specimens. Three scores were calculated, varying weights on specific symptoms: (1) influenza-like illness (ILI); (2) lower respiratory; and (3) all symptoms. For each score, we examined the daily mean score between those vaccinated and unvaccinated against influenza using weighted multivariable linear mixed effects and frailty models. Results: The study included 869 children (41% vaccinated, 47% female, 58% White, non-Hispanic) and 653 adults (42% vaccinated, 65% female, 72% White, non-Hispanic) with laboratory-confirmed influenza. In multivariable analyses, the mean difference in the daily ILI score was āˆ’0.16 (95% CI, āˆ’.32 to āˆ’.01) between vaccinated and unvaccinated children and āˆ’0.18 (95% CI, āˆ’.34 to āˆ’.01) for the lower respiratory score. There was no significant difference among adults. Influenza vaccination was not associated with time to symptom alleviation among children. However, ILI symptom alleviation occurred earlier among vaccinated (HR: 1.30; 95% CI, 1.04–1.62) adults. Conclusions: Ambulatory children with influenza who were vaccinated experienced less ILI symptom burden compared to those who were not vaccinated against influenza, but vaccination was not associated with symptom duration. Conversely, among ambulatory adults with influenza, vaccination and symptom burden were not associated, but vaccination was associated with faster alleviation of ILI symptoms.

  • Open Access

    Genomic Surveillance of Human Metapneumovirus in the United States, 2010–2025

    byĀ Emily E Bendall, William J Fitzsimmons, Weronika Damek Valvano, Rachel Truscon, Wesley H Self, Natasha Halasa, James D Chappell, Yuwei Zhu, Basmah Safdar, Adit A Ginde, et al.

    Background: Human metapneumovirus (HMPV) is a significant cause of acute respiratory illness in both children and adults, yet its genomic epidemiology remains understudied compared to other respiratory viruses. Methods: Hybrid capture and whole-genome sequencing were performed on 616 HMPV-positive specimens from 2 cohorts: the household-based HIVE study (2010–2022) in Michigan and the multicenter IVY network (2022–2025) of hospitalized adults. Consensus sequences were generated using IRMA, clades were annotated using Nextclade, and phylogenetic trees were constructed separately for HMPV-A and HMPV-B using IQ-TREE and TreeTime. Analysis of selection by dN/dS was performed using SLAC. Results: We obtained complete genomes from 325 specimens. Our analyses revealed the continued predominance of the A2.2.2 clade and little geographic structure in the United States. Genomic diversity was highest in the glycoprotein (G); we identified a shift from variants bearing the 180nt duplication to ones with a 111nt duplication. Phylogenetic analyses supported the duplication-deletion model for the origin of the duplications. The conserved fusion (F) protein showed limited antigenic variation and low rates of nonsynonymous substitutions Conclusions: These findings underscore the utility of enhanced genomic surveillance for understanding HMPV evolution and informing vaccine development. There was little genomic diversity in vaccine-targeted epitopes.


  • Severity of Clinical Presentation and Outcomes in Hospitalized Adult People With Influenza by Type and Subtype, United States—2017–2020

    byĀ Seana Cleary, Nathaniel M Lewis, H Keipp Talbot, Yuwei Zhu, Emily T Martin, Arnold S Monto, Manjusha Gaglani, Kempapura Murthy, Richard K Zimmerman, Fernanda P Silveira, et al.

    Background: While influenza A(H3N2)-predominant seasons tend to have increased rates of influenza-associated hospitalizations and deaths, little is known about differences in clinical presentation and hospitalization outcomes by influenza type and subtype. Methods: Data from hospitalized adults aged ≄18 years in 4 US states from 2017 to 2020 were used to evaluate the association between influenza type/subtype and severe influenza presentation and outcomes. Log binomial regression and modified Poisson regression with robust error variance were used to estimate adjusted risk ratios (aRRs) for clinical indicators within 24 hours of hospital admission and severity outcomes. Multivariable Cox proportional hazard models were used to estimate adjusted hazard ratios for length of hospital stay and intensive care unit (ICU) stay. All models were adjusted for underlying conditions, age group, influenza vaccination, and site. Results: People with influenza A(H1N1) were more likely to be admitted to an ICU (aRR = 1.42) than people with A(H3N2). People with influenza A(H1N1) had higher risk of hypoxemia (SpO2 38°C, aRR = 1.56). Conclusions: Adult people hospitalized with influenza A(H1N1) had a higher risk of multiple severity indicators. Better understanding of influenza severity related to both host and virus type is important for reducing the burden of severe influenza in adults.


  • Multimorbidity Profiles and Severe In-Hospital Outcomes in Adults With Respiratory Syncytial Virus

    byĀ Kevin C Ma, Diya Surie, Yuwei Zhu, Carlos G Grijalva, Paul W Blair, Basmah Safdar, Adit A Ginde, Ithan D Peltan, Samuel M Brown, Manjusha Gaglani, et al.

    Background: Adults hospitalized with acute respiratory infections, including respiratory syncytial virus (RSV), often have multiple underlying conditions. Few data are available on the combined effect of conditions on risk of severe outcomes from RSV disease. Methods: We enrolled adults hospitalized with RSV at 26 hospitals in 20 US states admitted January 2022–July 2024. Seventeen underlying conditions were selected after excluding those with rare prevalence (≤1%) or high pairwise correlation (≄0.7). We applied Bayesian profile regression to identify profiles of conditions associated with increased risk of RSV severe outcomes, stratifying among adults aged 18–59 and ≄60 years. Results: We analyzed data from 1111 adults hospitalized with RSV (median [IQR] age, 66 [53–75] years). Among 397 adults aged 18–59 years, 2 profiles were identified: (1) minimal prevalence with fewer underlying conditions and a posterior median intensive care unit (ICU) admission risk of 21% (95% credible interval, 16%–25%) and (2) cardiorenal/diabetes with frequent heart failure, chronic kidney disease, diabetes, and increased ICU admission risk (37% [27%–48%]). Among 714 adults aged 60 years and older, 4 profiles were identified: (1) minimal prevalence (ICU admission risk, 22% [18%–26%]), (2) cardiorenal/diabetes (27% [21%–34%]), (3) hematologic malignancy and transplant receipt (12% [6%–21%]), and (4) chronic pulmonary disease with home oxygen dependence (44% [25%–66%]). Conclusions: Distinct underlying condition profiles with varying risks of critical illness were observed among inpatients with RSV. These findings could support recognition of high-risk patients to inform RSV prevention strategies and suggest that the role of multimorbidity in severe RSV disease risk warrants further attention.


  • Vaccine Effectiveness Against Influenza A(H1N1), A(H3N2), and B-Associated Hospitalizations, United States, 1 September 2023 to 31 May 2024

    byĀ Nathaniel M Lewis, Elizabeth J Harker, Seana Cleary, Yuwei Zhu, Carlos G Grijalva, James D Chappell, Jillian P Rhoads, Adrienne Baughman, Jonathan D Casey, Paul W Blair, et al.

    Background: The 2023–2024 influenza season included sustained elevated activity from December 2023 to February 2024 and continued activity through May 2024. Influenza A(H1N1), A(H3N2), and B viruses circulated during the season. Methods: During 1 September 2023 to 31 May 2024, a multistate sentinel surveillance network of 24 medical centers in 20 US states enrolled adults aged ≄18 years hospitalized with acute respiratory illness. Consistent with a test-negative design, cases tested positive for influenza viruses by molecular or antigen test, and controls tested negative for influenza viruses and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Vaccine effectiveness (VE) against influenza-associated hospitalization was calculated as (1 āˆ’ adjusted odds ratio for vaccination) Ɨ 100%. Results: Among 7690 patients, including 1170 influenza cases (33% vaccinated) and 6520 controls, VE was 40% (95% confidence interval [CI], 31%–48%) with varying estimates by age: 18–49 years, 53% (95% CI, 34%–67%); 50–64 years, 47% (95% CI, 31%–60%); ≄ 65 years, 31% (95% CI, 16%–43%). Protection was similar among immunocompetent patients (40%; 95% CI, 30%–49%) and immunocompromised patients (32%; 95% CI, 7%–50%). VE was statistically significant against influenza B (67%; 95% CI, 35%–84%) and A(H1N1) (36%; 95% CI, 21%–48%) and crossed the null against A(H3N2) (19%; 95% CI, āˆ’8% to 39%). VE was higher for patients 14–60 days from vaccination (54%; 95% CI, 40%–65%) than >120 days (18%; 95% CI, āˆ’1% to 33%). Conclusions: During 2023–2024, influenza vaccination reduced the risk of influenza A(H1N1)- and influenza B-associated hospitalizations among adults; effectiveness was lower in patients vaccinated >120 days prior to illness onset compared with those vaccinated 14–60 days prior.


  • Ongoing Symptoms After Acute SARS-CoV-2 or Influenza Infection in a Case-Ascertained Household Transmission Study: 7 US Sites, 2021–2023

    byĀ Ayla Bullock, Alexandra F Dalton, Melissa S Stockwell, Son H McLaren, Ellen Sano, Huong Q Nguyen, Suchitra Rao, Edwin Asturias, Karen Lutrick, Katherine D Ellingson, et al.

    Background: The prevalence and risk factors for ongoing symptoms following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [SCV2]) or influenza infection are not well characterized. We conducted a prospective cohort study of households wherein ≄1 individual was infected with SCV2 or influenza to evaluate prevalence of and factors associated with ongoing symptoms at 90 days. Methods: Index cases and their household contacts provided baseline health and sociodemographic information and collected daily respiratory specimens for 10 days following enrollment. Participants completed a follow-up survey 90 days after enrollment to characterize ongoing symptoms. Results: We analyzed 1967 participants enrolled between December 2021 and May 2023. The risk of ongoing symptoms did not differ by infection status in SCV2 (SCV2-positive: 15.6%; SCV2-negative: 13.9%; odds ratio [OR]: 1.14; 95% CI: .7–1.69) or influenza (influenza-positive: 8.8%; influenza-negative: 10.0%; OR: .87; 95% CI: .45–1.72) households. However, among study participants with a documented infection, SCV2-positive participants had nearly twice the odds of ongoing symptoms as influenza-positive participants (OR: 1.92; 95% CI: 1.27–2.97). Conclusions: These results suggest that SCV2 households have a significantly higher prevalence of ongoing symptoms compared with influenza households (OR: 1.78; 95% CI: 1.28–2.47). Among participants with SCV2 infection, underlying conditions (adjusted OR [aOR]: 2.65; 95% CI: 1.80–3.90) and coronavirus disease 2019 (COVID-19)–like symptoms (aOR: 2.92; 95% CI: 1.15–7.43) during acute infection increased odds of ongoing symptoms at 90 days, whereas hybrid immunity reduced the odds of ongoing symptoms (aOR: 0.44; 95% CI: .22–.90).


  • Serious Neurologic Events With Seasonal Influenza in Young Children

    byĀ Brooke P. Quertermous, Derek J. Williams, Jean Bruce, Mert Sekmen, Yuwei Zhu, Carlos G. Grijalva, James W. Antoon